LINDA TRINH: Open Payments
NPI 1124333828 · IRVINE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$205,338 in 378 payments from 21 companies in 2025. Trend: 2023 $210,770 · 2024 $199,340 · 2025 $205,338
Speaker / faculty: $156,604Travel & lodging: $23,315Consulting: $16,310Food & beverage: $9,109
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 91 | $67,758 |
| Alkermes, Inc. | 82 | $49,027 |
| Neurocrine BioSciences, Inc. | 62 | $48,747 |
| Teva Pharmaceuticals USA, Inc. | 35 | $17,094 |
| ABBVIE INC. | 45 | $12,553 |
| E.R. Squibb & Sons, L.L.C. | 19 | $7,929 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $1,060 |
| Vanda Pharmaceuticals Inc. | 9 | $244 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $192 |
| Otsuka America Pharmaceutical, Inc. | 6 | $151 |
Products named: INGREZZA, INVEGA SUSTENNA, LYBALVI, SPRAVATO, ARISTADA, VRAYLAR, UZEDY, COBENFY.
Industry payments across CA — which companies pay providers there.
